Skip to content
Subscriber Only
Business
Prognosis

FDA Chief Promises Transparency for Covid-19 Vaccine Review

  • ‘We’re going to let the data’ dictate vaccine look, Hahn says
  • FDA’s Hahn speaks in interview with Bloomberg News on Sunday
Video player cover image
FDA Walks Back Claim of Covid Therapy
Updated on

The head of the U.S. Food and Drug Administration promised that the review of a potential Covid-19 vaccine in the U.S. will be transparent to the public, with any clearance by the agency driven by data alone.

In an interview on Sunday, Commissioner Stephen Hahn responded to questions about the different ways the FDA could clear a vaccine for use: either under an emergency authorization, likely based on more limited data and for use in a narrow group, or a broader approval that could lead to wider use.